Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Affimed N.V. (AFMD)

Affimed N.V. (AFMD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 290,474
  • Shares Outstanding, K 76,240
  • Annual Sales, $ 23,960 K
  • Annual Income, $ -36,250 K
  • 60-Month Beta 2.72
  • Price/Sales 12.03
  • Price/Cash Flow N/A
  • Price/Book 8.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.12
  • Number of Estimates 2
  • High Estimate -0.10
  • Low Estimate -0.14
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.45 +10.43%
on 07/31/20
4.91 -22.40%
on 07/09/20
-0.58 (-13.21%)
since 07/07/20
3-Month
1.88 +102.66%
on 05/14/20
4.91 -22.40%
on 07/09/20
+1.61 (+73.18%)
since 05/07/20
52-Week
1.42 +168.31%
on 03/17/20
4.91 -22.40%
on 07/09/20
+1.08 (+39.56%)
since 08/07/19

Most Recent Stories

More News
Affimed N.V. (AFMD) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Affimed N.V. (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AFMD : 3.81 (+0.79%)
Affimed N.V.: 1Q Earnings Snapshot

HEIDELBERG, Germany (AP) _ Affimed N.V. (AFMD) on Tuesday reported a first-quarter loss of $9.1 million, after reporting a profit in the same period a year earlier.

AFMD : 3.81 (+0.79%)
Affimed (AFMD) Catches Eye: Stock Jumps 7.2%

Affimed (AFMD) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

AFMD : 3.81 (+0.79%)
AKCA : 11.60 (+1.13%)
All You Need to Know About Affimed N.V. (AFMD) Rating Upgrade to Buy

Affimed N.V. (AFMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AFMD : 3.81 (+0.79%)
Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies

NEW YORK, NY / ACCESSWIRE / March 24, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a Virtual Conference Series on March...

AFMD : 3.81 (+0.79%)
APM : 3.54 (-0.28%)
CATB : 6.51 (+0.93%)
EPIX : 6.83 (+0.74%)
EVFM : 2.93 (+1.03%)
PIRS : 2.70 (-2.17%)
SLGL : 7.36 (-1.87%)
New Strong Sell Stocks for November 27th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

SGSOY : 26.2800 (-0.11%)
ASYS : 4.93 (-3.52%)
AFMD : 3.81 (+0.79%)
WLL : 0.9026 (-2.95%)
COHR : 127.97 (+0.61%)
Affimed N.V. (AFMD) Reports Q3 Loss, Misses Revenue Estimates

Affimed N.V. (AFMD) delivered earnings and revenue surprises of -35.71% and -65.47%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

AFMD : 3.81 (+0.79%)
Affimed N.V.: 3Q Earnings Snapshot

HEIDELBERG, Germany (AP) _ Affimed N.V. (AFMD) on Tuesday reported a loss of $12.1 million in its third quarter.

AFMD : 3.81 (+0.79%)
Affimed N.V. (AFMD) Reports Q2 Loss, Misses Revenue Estimates

Affimed N.V. (AFMD) delivered earnings and revenue surprises of 0.00% and -30.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

AFMD : 3.81 (+0.79%)
Affimed N.V.: 2Q Earnings Snapshot

HEIDELBERG, Germany (AP) _ Affimed N.V. (AFMD) on Wednesday reported a loss of $11.6 million in its second quarter.

AFMD : 3.81 (+0.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade AFMD with:

Business Summary

Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V.,...

See More

Key Turning Points

2nd Resistance Point 4.03
1st Resistance Point 3.92
Last Price 3.81
1st Support Level 3.72
2nd Support Level 3.63

See More

52-Week High 4.91
Last Price 3.81
Fibonacci 61.8% 3.58
Fibonacci 50% 3.16
Fibonacci 38.2% 2.75
52-Week Low 1.42

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar